Pharmaceutical Executive, Jul 1, 2004 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jul 1, 2004
Executive Profile
Think Small Grow Big
By Joanna Breitstein
After Adderall, what's next for Shire? CEO Matthew Emmens thinks the answer lies in a simple strategy.
Columns
Training During Transition
By John Kuchna
During the change phase, it is critical that communications in the field remain consistent and that customers perceive little or no disruption in the quality of the sales call.
Features
Pricing Climate Heats Up in US and Europe
By Neil Turner
In 2003, Big Pharma produced only a dozen new drugs. At the same time, it came under new pressure to create value from those thin pipelines. In that "hot squeeze" of a climate, pharma companies needed price premiums for every product in every market. They were more successful in some countries than in others. Other pricing trends also took their toll.
Stop Giving Away Your Secrets
By Michael D. Lam
Big pharma companies aggressively gather sensitive intelligence about their competitors, but few, strangely, make a systematic effort to protect their own.
One World, One Voice
By Bruno Delagneau, MD
Critics often claim that international marketing programs ignore fundamental differences that exist across countries and cultures.

ADVERTISEMENT

Click here